| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2018-09-05 | MIN-102 ( hydroxypioglitazone -5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride) | patients with the AMN (adrenomyeloneuropathy) phenotype of X-linked adrenoleukodystrophy (X-ALD) | 2-3 | Minoryx Therapeutics (Spain) | Rare diseases - Genetic diseases |
| 2018-09-05 | LYS-SAF302 | mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) | 2-3 | Lysogene (France) | Rare diseases - Genetic diseases |
| 2018-09-04 | BI-1206 and rituximab | relapsed or refractory non-Hodgkin lymphoma (NHL) including mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma | 1-2 | BioInvent (Sweden) | Cancer - Oncology |
| 2018-09-03 | BioInvent (Sweden) | Cancer - Oncology - Technology - Services | |||
| 2018-08-31 | anifrolumab | moderate-to-severe systemic lupus erythematosus (SLE) | 3 | AstraZeneca (UK) | Autoimmune diseases |
| 2018-08-30 | domagrozumab -PF-06252616 | Duchenne muscular dystrophy (DMD) | 2 | Pfizer (USA - NY) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2018-08-29 | aducanumab (BIIB037) | Alzheimer's disease (AD) | 1b | Biogen (USA - MA) | Neurodegenerative diseases |
| 2018-08-28 | elafibranor - GFT505 | primary biliary cholangitis (PBC) | 2 | Genfit (France) | Liver diseases - Hepatic diseases |
| 2018-08-27 | Xarelto® (rivaroxaban) | patients with chronic heart failure (HF) and significant coronary artery disease (CAD) | 3 | Bayer HealthCare (Germany) Janssen Research & Development (J&J) (USA - NJ) | Cardiovascular diseases |
| 2018-08-24 | stem cell-derived exosomes | atopic dermatitis | preclinical | Exocobio (Republic of Korea) | Autoimmune diseases - Dermatological diseases |
| 2018-08-16 | fasinumab | moderate-to-severe osteoarthritis pain of the hip or knee | 3 | Regeneron Pharmaceuticals (USA - NY) Teva Pharmaceutical (Israel) | Rheumatic diseases - Inflammatory diseases |
| 2018-08-16 | INO-5401, INO-9012 and atezolizumab | bladder cancer | 1-2a | Inovio Pharmaceuticals (USA - PA) Roche (Switzerland) | Cancer - Oncology |
| 2018-08-16 | CT-P16 (biosimilar version of bevacizumab - Avastin®) | breast cancer | 3 | Celltrion Healthcare (South Korea) | Cancer - Oncology |
| 2018-08-16 | EDIT-101 | Leber congenital amaurosis type 10 (LCA10) | 1 | Editas Medicine (USA - MA) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2018-08-15 | cabotegravir and rilpivirine | HIV-1 infection | 3 | ViiV Healthcare (UK - USA) | Infectious diseases |
| 2018-08-09 | Remsima® SC (biosimilar infliximab) | 3 | Celltrion Healthcare (South Korea) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | |
| 2018-08-09 | tislelizumab (BGB-A317) | Stage IIIB or IV squamous non-small cell lung cancer (NSCLC). | 3 | BeiGene (China) | Cancer - Oncology |
| 2018-08-07 | BL-8040 in combination with G-CSF | mobilization of hematopoietic stem cells (HSCs) used for autologous transplantation in multiple myeloma patients | 3 | BiolineRX (Israël) | Cancer - Oncology |
| 2018-08-07 | CT-P17 (biosimilar version of Humira® - adalimumab) | rheumatoid arthritis | 1 | Celltrion Healthcare (South Korea) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2018-08-07 | CT-P17 (biosimilar version of Humira® - adalimumab) | rheumatoid arthritis | 3 | Celltrion Healthcare (South Korea) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
